The Vanguard Group 13D and 13G filings for Catalyst Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-13 5:00 pm Purchase |
2023-12-29 | 13G | Catalyst Pharmaceuticals, Inc. CPRX |
The Vanguard Group | 7,120,417 6.680% |
351,676 (+5.20%) |
Filing |
| 2023-02-09 11:12 am Purchase |
2022-12-30 | 13G | Catalyst Pharmaceuticals, Inc. CPRX |
The Vanguard Group | 6,768,741 6.500% |
1,932,428 (+39.96%) |
Filing |
| 2022-02-09 3:33 pm Sale |
2021-12-31 | 13G | Catalyst Pharmaceuticals, Inc. CPRX |
The Vanguard Group | 4,836,313 4.690% |
-934,766 (-16.20%) |
Filing |
| 2021-02-10 10:39 am Purchase |
2020-12-31 | 13G | Catalyst Pharmaceuticals, Inc. CPRX |
The Vanguard Group | 5,771,079 5.570% |
5,771,079 (New Position) |
Filing |